Home

Novo Nordisk A/S Common Stock (NVO)

65.29
-1.75 (-2.61%)
NYSE · Last Trade: Jul 17th, 6:10 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close67.04
Open66.18
Bid65.29
Ask65.39
Day's Range64.87 - 66.41
52 Week Range57.00 - 142.23
Volume9,023,925
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield2.198 (3.37%)
1 Month Average Volume7,659,632

Chart

About Novo Nordisk A/S Common Stock (NVO)

Novo Nordisk A/S is a global healthcare company focused on developing and manufacturing innovative pharmaceuticals, primarily in the fields of diabetes care and hormone replacement therapy. With a strong emphasis on research and development, the company aims to improve the lives of patients with chronic conditions by providing high-quality medications and medical devices. Novo Nordisk is recognized for its comprehensive approach to diabetes management, including insulin products and modern delivery systems, while also expanding its portfolio to address other serious conditions, such as obesity and rare blood disorders. The company operates in numerous countries, combining expertise in biotechnology with a commitment to sustainability and corporate responsibility. Read More

News & Press Releases

Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aislesbenzinga.com
GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs altering consumer purchasing patterns.
Via Benzinga · July 17, 2025
Hims & Hers Health Is Looking to Cash In on This Novo Nordisk Blunderfool.com
Via The Motley Fool · July 16, 2025
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock at a Reasonable Valuationchartmill.com
NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks in the pharmaceutical sector.
Via Chartmill · July 16, 2025
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'benzinga.com
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
Via Benzinga · July 16, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · July 15, 2025
3 Absurdly Cheap Growth Stocks to Load Up On Right Nowfool.com
Via The Motley Fool · July 15, 2025
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetesbenzinga.com
An update on Sana Biotechnology.
Via Benzinga · July 14, 2025
3 Dividend Growth Stocks to Buy and Holdfool.com
Via The Motley Fool · July 12, 2025
Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing'benzinga.com
Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate.
Via Benzinga · July 11, 2025
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lillyfool.com
Via The Motley Fool · July 9, 2025
Zepbound Powers Eli Lilly's Upbeat Q2 Outlookbenzinga.com
BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady.
Via Benzinga · July 9, 2025
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focusstocktwits.com
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%.
Via Stocktwits · July 9, 2025
Novo Nordisk Seeks Approval For Higher Wegovy Dose In Europestocktwits.com
In addition to the submission to the EMA, Novo Nordisk aims to make the higher dose of Wegovy widely available throughout the European Union.
Via Stocktwits · July 8, 2025
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approvalbenzinga.com
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.
Via Benzinga · July 8, 2025
WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformationbenzinga.com
WeightWatchers completes reorganization, adds new leadership and unveils a women's health initiative targeting menopause care.
Via Benzinga · July 8, 2025
2 S&P 500 Dividend Stocks That Could Climb 17% or More, According to Wall Streetfool.com
Via The Motley Fool · July 8, 2025
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaroundbenzinga.com
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.
Via Benzinga · July 7, 2025
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuitsbenzinga.com
Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns.
Via Benzinga · July 7, 2025
Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expertbenzinga.com
Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access.
Via Benzinga · July 7, 2025
Better Growth Buy: Eli Lilly vs. Viking Therapeuticsfool.com
Via The Motley Fool · July 7, 2025
2 Stocks to Buy on the Dip and Hold for 10 Yearsfool.com
Via The Motley Fool · July 6, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · July 2, 2025
Is Hims & Hers Stock in Trouble?fool.com
Via The Motley Fool · July 2, 2025
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Reportbenzinga.com
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.
Via Benzinga · July 1, 2025
Amazon Wants More Powerfool.com
Amazon's latest data center will reportedly require the same amount of electricity as 1 million homes.
Via The Motley Fool · July 1, 2025